Dr. Oliver Sartor recently gave a presentation for a Medscape CME event that was titled, “Evaluating the Totality of Evidence: Management of Locally Advanced and Metastatic Prostate Cancer.” He included a slide showing the comparative side effect profiles of enzalutamide (Xtandi) – ENZA, apalutamide (Erleada) – APA and darolutamide – DARO. Darolutamide appears to have a more favorable side effect profile when compared to Xtandi or Erleada, especially with regard to fatigue and cognitive deficit. Darolutamide is expected to be approved by the FDA later this year.
